Frankfurt
10.07.25 | 08:05
0,089 Euro
-0,45 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,126 | 0,134 | 22:16 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 19:18 | Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure | 281 | Business Wire | Bridge financing through the issuance of convertible bonds to Vester Finance and European investors for €1.8m Immediate receipt of the entire financing upon signing Cash runway extended to... ► Artikel lesen | |
| 17:48 | Mauna Kea Technologies Reaches Key Milestone in its Safeguard Procedure | 175 | Business Wire | Structuring of financing in progress to secure the safeguard period and support long-term development plan Authorization to implement the classes of affected parties proceeding, paving the way... ► Artikel lesen | |
| Mo | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 172 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 05.06. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 278 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 05.06. | Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 5, 2025 | 394 | Business Wire | All the resolutions proposed by the Board of Directors were adopted
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and... ► Artikel lesen | |
| 02.06. | Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification | 411 | Business Wire | Cellvizio technology combined with AI outperforms human experts in pancreatic cyst risk stratification, a major breakthrough for patient management Results build on new CLIMB study data recently... ► Artikel lesen | |
| 21.05. | Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress | 372 | Business Wire | Ongoing Strategic Negotiations Towards a Licensing Agreement Strong Momentum for CellTolerance: Over 1,500 Procedures Completed, New Centers of Excellence Adopting the Technology, Including a... ► Artikel lesen | |
| 20.05. | Mauna Kea Technologies Announces the Availability of Preparatory Documents for the Combined General Meeting of June 5, 2025 and the Instructions for Participation | 605 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 06.05. | Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week 2025 | 794 | Business Wire | Over 75 physicians attended educational presentations about the breakthrough impact of needle-based Confocal Laser Endomicroscopy and AI on the diagnosis and treatment of pancreatic cystic lesions... ► Artikel lesen | |
| 05.05. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 577 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 30.04. | Mauna Kea Technologies: Publication of the 2024 Annual Financial Report | 746 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 28.04. | Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio in Key Indications | 352 | Business Wire | Pancreatic cyst abstracts build on endorsement of Cellvizio by Europe's leading endoscopy society, ESGE, as a key tool for improving pancreatic cyst diagnostic accuracy AI, pancreatic cancer... ► Artikel lesen | |
| 24.04. | Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update | 869 | Business Wire | Commercial activities remain strong, including CellTolerance launch Recently approved safeguard proceeding yielding productive creditor and investor discussions aimed at strengthening Mauna Kea's... ► Artikel lesen | |
| 07.04. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 266 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF Listing: Euronext Growth Paris
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing:... ► Artikel lesen | |
| 01.04. | Mauna Kea Technologies Announces Entrance Into Exclusive Negotiations for a Licensing Agreement for Cellvizio in an Important Therapeutic Area With a Major Industry Player | 384 | Business Wire | The Company also confirms that it is pursuing licensing discussions in other therapeutic areas The protective framework of the safeguard proceedings enables Mauna Kea Technologies to intensify... ► Artikel lesen | |
| 31.03. | Mauna Kea Technologies Announces the Opening of a Safeguard Proceeding to Restructure Its Financial Liabilities | 611 | Business Wire | The aim of the procedure is to optimize the Company's financial structure in order to adapt it to the needs of its future growth The procedure will also provide a protective framework favorable... ► Artikel lesen | |
| 06.03. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 299 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.03. | Mauna Kea Technologies: Cellvizio Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis | 351 | Business Wire | ESGE, Europe's leading endoscopy society, endorses Cellvizio® as a key tool for improving pancreatic cyst diagnostic accuracy, marking a major step towards broader commercial adoption
Regulatory... ► Artikel lesen | |
| 06.02. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 310 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 27.01. | Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio for Precision Surgery in Head and Neck Cancers | 429 | Business Wire | Cellvizio was successfully integrated into TransOral Robotic Surgery (TORS) procedures to assess peripheral mucosal margins in the larynx, oropharynx and hypopharynx Cellvizio helped identify... ► Artikel lesen |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,103 | +5,10 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
| FAMICORD | 4,860 | -4,71 % | Original-Research: FamiCord AG (von Montega AG): Kaufen | Original-Research: FamiCord AG - von Montega AG 06.06.2025 / 17:08 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den Inhalt der Mitteilung... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,320 | +2,47 % | Geratherm Medical AG: GJ24 war herausfordernd, vorsichtige Prognose für GJ25; mwb research bekräftigt KAUFEN | Die Ergebnisse von Geratherm für das Geschäftsjahr 2024 zeigten einen Umsatzrückgang von 33% auf 14,0?Mio.?EUR, was in erster Linie auf deutliche Rückgänge in den Bereichen Healthcare Diagnostics und... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,356 | +1,80 % | Plus Therapeutics Inc.: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases | HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,755 | -1,05 % | Atossa Therapeutics, Inc.: Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines... ► Artikel lesen | |
| MEDICLIN | 2,940 | 0,00 % | EQS-News: MEDICLIN AG: Ordentliche Hauptversammlung stimmt allen Beschlussvorschlägen zu | EQS-News: MEDICLIN AG
/ Schlagwort(e): Hauptversammlung
MEDICLIN AG: Ordentliche Hauptversammlung stimmt allen Beschlussvorschlägen zu
04.06.2025 / 13:27 CET/CEST
Für... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results | Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss improved... ► Artikel lesen | |
| VERU | 0,510 | +8,88 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
| LIFEWARD | 0,741 | -2,72 % | Lifeward Ltd.: Administrative Law Judge Determines ReWalk Personal Exoskeleton is "Reasonable and Necessary" for Medicare Beneficiary | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| LIGHT AI | 0,156 | -8,53 % | Light AI Inc: Light AI talks up development of wellness application | ||
| EKSO BIONICS | 3,430 | -4,46 % | XFRA 23E0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEKSO BIONICS. NEW... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 47,850 | +0,95 % | Aktien Frankfurt Ausblick: Dax moderat höher erwartet - Drohende Zölle im Fokus | FRANKFURT (dpa-AFX) - Der Dax steuert nach der mäßigen Vorwoche am Montag auf eine freundliche Eröffnung zu. Allerdings dürfte die nahende Deadline für eine Lösung des Handelskonflikts zwischen den... ► Artikel lesen | |
| GERRESHEIMER | 50,50 | +4,47 % | Aktie von Gerresheimer legt um 0,57 Prozent zu (49,02 €) | Die Aktie von Gerresheimer notiert heute etwas fester. Die Aktie notiert aktuell bei 49,02 Euro. Die Aktie von Gerresheimer verzeichnet gegenwärtig ein Kursplus von 0,57 Prozent. Sie hat sich um 28... ► Artikel lesen | |
| FRESENIUS | 42,220 | -0,14 % | Neue 7,00% Aktienanleihe auf Fresenius | Düsseldorf (www.anleihencheck.de) - Die HSBC Trinkaus & Burkhardt AG, Düsseldorf, bietet ab dem 03. Juli 2025 eine neue Aktienanleihe (ISIN DE000HT6HF83/ WKN HT6HF8) auf die Aktie von Fresenius (ISIN... ► Artikel lesen |
Das Unternehmen MAUNA KEA TECHNOLOGIES kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (-0,45 %) liegt der Kurs bei 0,089 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.